Sars-Cov-2 Infection among Hospitalized Patients with Chronic Kidney Disease

ABSTRACT

Introduction: In Mongolia, a total of 922000 patients have had COVID-19 infection in the last 2 years, and 2179 (0.24%) of them have died. Mongolia is considered as one of the countries that has successfully responded to COVID-19 pandemic due to its intensive vaccination, hospitalization of at-risk population and severe patients, and relatively low mortality rate. International studies reported that chronic kidney disease (CKD) increases risk of severe disease, adverse events and complications among COVID-19 patients. We aim to study COVID-19 clinical courses and prognosis in patients with CKD. Method(s) We have collected data from medical records of the First Central Hospital of Mongolia (FCHM) from April, 2021 to March, 2022 and data was assessed with the SPSS program. Result(s) We enrolled 125 patients in our study. Average age was 50.7+/-15.1 and 67(53.6%) of them were male, 58(46.4%) of them were female. 50(40%) patients were in CKD stage 1-4 (non-dialysis patients) and 75(60%) patients were in CKD stage 5 (dialysis patients). Among 125 patients, mild, moderate, severe, very-severe cases were 3(2.4%), 60(48%), 56(44.8%), and 6(4.8%) respectively. 15(12%) patients were treated in ICU, 9(7.2%) patients needed ventilator support, and 5(4%) patients died. Clinically, fever, cough, dyspnea, sore-throat, gastrointestinal symptoms, fatigue, and chest pain presented in 49(39.2%), 94(75.2%), 64(51.2%), 29(23.2%), 19(15.2%), 79(63.2%), and 32(25.6%) patients, respectively. 62(49.6% of total) patients were classified as severe and very-severe, 40(32%) of them were in CKD stage 5. 99(79.2%) patients of all patients were vaccinated against SARS-CoV-2 infection. 90(72%) have received remdesivir, 80(64%) patients have had steroid treatment. Conclusion(s) Dialysis patients had a tendency to have complications of COVID-19. We conclude that hospitalized patients with CKD at risk may have reduced the patient's risk of complications and affected prognosis. No conflict of interestCopyright © 2023